PDB63 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN TREATMENT IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC HEART FAILURE BASED ON SUBGROUP OF EMPA-REG OUTCOME IN THE UNITED KINGDOM
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.768
https://www.valueinhealthjournal.com/article/S1098-3015(18)34068-3/fulltext
Title :
PDB63 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN TREATMENT IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC HEART FAILURE BASED ON SUBGROUP OF EMPA-REG OUTCOME IN THE UNITED KINGDOM
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)34068-3&doi=10.1016/j.jval.2018.09.768
First page :
Section Title :
Open access? :
No
Section Order :
165